(Q47556747)

3 February 2018

title

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations (English)

1 reference

3 February 2018

1 reference

0 references

Poliovirus

1 reference

2

Mark A Pallansch

1 reference

3 February 2018

Radboud J Duintjer Tebbens

1

Radboud J Duintjer Tebbens

1 reference

3 February 2018

Stephen Cochi

3

Stephen L Cochi

1 reference

3 February 2018

Steven Wassilak

9

Steve G F Wassilak

1 reference

3 February 2018

Kimberly M. Thompson

10

Kimberly M Thompson

1 reference

3 February 2018

author name string

Derek T Ehrhardt

4

1 reference

3 February 2018

Noha H Farag

5

1 reference

3 February 2018

Stephen C Hadler

6

1 reference

3 February 2018

Lee M Hampton

7

1 reference

3 February 2018

Maureen Martinez

8

1 reference

3 February 2018

publication date

3 January 2018

1 reference

3 February 2018

published in

Risk Analysis

1 reference

3 February 2018

Economic analysis of the global polio eradication initiative.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Monitoring and Validation of the Global Replacement of tOPV with bOPV, April-May 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

An economic analysis of poliovirus risk management policy options for 2013-2052

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Poliovirus vaccination during the endgame: insights from integrated modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Expert review on poliovirus immunity and transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Polio eradication. Efficacy of inactivated poliovirus vaccine in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

The potential impact of expanding target age groups for polio immunization campaigns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling the dynamics of oral poliovirus vaccine cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Progress and peril: poliomyelitis eradication efforts in Pakistan, 1994-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Polio eradication initiative in Afghanistan, 1997-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Quantifying the impact of expanded age group campaigns for polio eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

The role of older children and adults in wild poliovirus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

New strategies for the elimination of polio from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Genomic Surveillance Elucidates Persistent Wild Poliovirus Transmission During 2013-2015 in Major Reservoir Areas of Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Preeradication vaccine policy options for poliovirus infection and disease control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRISA.12962

Progress toward poliomyelitis eradication--Pakistan, 1994-1998.

21 January 2018

1 reference

12 December 2020

Insidious reintroduction of wild poliovirus into Israel, 2013.

1 reference

12 December 2020

Possible eradication of wild poliovirus type 3--worldwide, 2012.

1 reference

12 December 2020

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

1 reference

12 December 2020

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

1 reference

12 December 2020

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use

1 reference

12 December 2020

Identifiers

DOI

10.1111/RISA.12962

1 reference

3 February 2018

PMC publication ID

7879700

0 references

1 reference

3 February 2018